Publicacions (114) Publicacions de Miguel Angel Canales Albendea

filter_list

2025

  1. IL-10 from tumoral B cells modulates the diffuse large B-cell lymphoma microenvironment and response to immunotherapy

    Blood, Vol. 145, Núm. 23, pp. 2746-2761

2024

  1. Product Attributes of CAR T-cell Therapy Differentially Associate with Efficacy and Toxicity in Second-line Large B-cell Lymphoma (ZUMA-7)

    Blood cancer discovery, Vol. 5, Núm. 1, pp. 21-33

2023

  1. COVID-19 Severity and Survival over Time in Patients with Hematologic Malignancies: A Population-Based Registry Study

    Cancers, Vol. 15, Núm. 5

  2. Comparative analysis of CAR T-cell therapy access for DLBCL patients: associated challenges and solutions in the four largest EU countries

    Frontiers in Medicine, Vol. 10

  3. Low Plasma Levels of Hyaluronic Acid Might Rule Out Sinusoidal Obstruction Syndrome after Hematopoietic Stem Cell Transplantation

    Disease Markers, Vol. 2023

  4. Obinutuzumab Can Be Administered as a 90-minute Short Duration Infusion in Patients with Previously Untreated Follicular Lymphoma: GAZELLE End of Induction Analysis

    HemaSphere

  5. Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study

    eClinicalMedicine, Vol. 63

2022

  1. A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results

    Leukemia and Lymphoma, Vol. 63, Núm. 1, pp. 93-100

  2. Comparison of the Effectiveness and Safety of the Oral Selective Inhibitor of Nuclear Export, Selinexor, in Diffuse Large B Cell Lymphoma Subtypes

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 1, pp. 24-33

  3. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell Lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 7, pp. 483-494

  4. IBCL-249 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results From a Phase I/II Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, pp. S387

  5. Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

    The Lancet Oncology, Vol. 23, Núm. 8, pp. 1055-1065

  6. The Association between Patient Characteristics and the Efficacy and Safety of Selinexor in Diffuse Large B-Cell Lymphoma in the SADAL Study

    Cancers, Vol. 14, Núm. 3

2021

  1. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

    Investigational New Drugs, Vol. 39, Núm. 4, pp. 1028-1035

  2. COVID-19 in patients with hematological malignancies: Considering the role of tyrosine kinase inhibitors

    Cancer

  3. Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma

    Future Oncology, Vol. 17, Núm. 11, pp. 1295-1310

  4. Hematopoietic cell transplantation during COVID-19 pandemic: experience from a tertiary hospital in Madrid

    Expert Review of Hematology

  5. Lessons learned for successful treatment of AML in the second wave of COVID-19 outbreak

    Leukemia and Lymphoma

  6. Survival among patients with relapsed/refractory diffuse large B cell lymphoma treated with single-agent selinexor in the SADAL study

    Journal of Hematology and Oncology

2020

  1. Agreements and uncertainties in autologous haematopoietic stem cell mobilization and collection. A Spanish consensus document

    Bone Marrow Transplantation, Vol. 55, Núm. 4, pp. 811-817